Lars Peters Lars.Peters@regionh.dk
Jürgen Rockstroh email@example.com
Co-infection with hepatitis B (HBV) or C (HCV) remain common and clinically important among HIV infected individuals.
Although effective therapy is now available for both HBV and HCV, its use and long-term clinical outcome in a diverse real-life setting are still not well described.
To study the long-term effect of HBV and HCV therapy and other factors on the development of hepatic and extra-hepatic morbidity and mortality in HIV/viral hepatitis co-infected persons enrolled in RESPOND
In the RESPOND Hepatitis Scientific Interest Group, clinicians and biostatisticians will develop and execute specific hepatitis research projects to address relevant questions in HIV/viral hepatitis co-infection research